Paragon 28, Inc. (FNA): Price and Financial Metrics
FNA Price/Volume Stats
|Current price||$12.05||52-week high||$21.49|
|Prev. close||$12.06||52-week low||$11.67|
|Day high||$12.05||Avg. volume||315,820|
|50-day MA||$14.26||Dividend yield||N/A|
|200-day MA||$17.08||Market Cap||994.67M|
FNA Stock Price Chart Interactive Chart >
FNA POWR Grades
- FNA scores best on the Sentiment dimension, with a Sentiment rank ahead of 79.78% of US stocks.
- FNA's strongest trending metric is Momentum; it's been moving down over the last 177 days.
- FNA's current lowest rank is in the Quality metric (where it is better than 7.99% of US stocks).
FNA Stock Summary
- PARAGON 28 INC's stock had its IPO on October 15, 2021, making it an older stock than only 3.18% of US equities in our set.
- With a price/sales ratio of 5.31, PARAGON 28 INC has a higher such ratio than 81.68% of stocks in our set.
- Over the past twelve months, FNA has reported earnings growth of 139.46%, putting it ahead of 90.5% of US stocks in our set.
- If you're looking for stocks that are quantitatively similar to PARAGON 28 INC, a group of peers worth examining would be XGN, MYGN, VISL, HAE, and XERS.
- To dig deeper into the stock's financial statements, go to FNA's page on browse-edgar?action=getcompany&CIK=0001531978.
FNA Valuation Summary
- FNA's price/sales ratio is 5.3; this is 178.95% higher than that of the median Healthcare stock.
- FNA's price/earnings ratio has moved down 539.4 over the prior 24 months.
Below are key valuation metrics over time for FNA.
Paragon 28, Inc. (FNA) Company Bio
Paragon 28, Inc. designs, develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. It offers plating systems, such as gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback ankle fusion plating systems. The company also provides precision guide technology for various procedures consisting of MTP fusion, a procedure to address bunion deformities that fuses two bones on the big toe; first tarsometatarsal arthrodesis; and metatarsal osteotomy for bunion correction, medial column beaming for charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis. In addition, it offers monster, mini monster, and joust beaming screw systems for use in bone reconstruction, osteotomy, arthrodesis, joint fusion, ligament fixation, fracture repair, and fracture fixation; APEX 3D total ankle replacement systems; total talus spacers to replace the talus and bone in the ankle that connects the leg and foot; bunion or hallux valgus correction systems; phantom intramedullary nail systems for the treatment of severe hallux valgus; and various orthobiologics, such as bone wedges, grafts, demineralized bone matrices, bone void fillers, synthetic materials, amniotic products, and a biocompatible collagen matrix, as well as PRESERVE bone graft systems for homologous application. Further, the company provides hammertoe implants, titanium wedges, and soft tissue fixators, as well as products for the various procedure, such as bunions, flatfoot, fracture fixation, and foot fracture. It serves hospitals and ambulatory surgery centers through a network of sales representatives and stocking distributors. Paragon 28, Inc. was incorporated in 2010 and is headquartered in Englewood, Colorado.
FNA Latest News Stream
|Loading, please wait...|
FNA Latest Social Stream
View Full FNA Social Stream
Latest FNA News From Around the Web
Below are the latest news stories about PARAGON 28 INC that investors may wish to consider to help them evaluate FNA as an investment opportunity.
Paragon 28®, Inc. Receives FDA Approval for IDE Feasibility Study of Its SMART Total Talus™ System for use in Conjunction with the APEX 3D™ Total Ankle Replacement System
ENGLEWOOD, Colo., September 11, 2023--Paragon 28, Inc. (NYSE: FNA), announced today they have received an Investigational Device Exemption (IDE) approval from the FDA to commence a feasibility study for configurations of the SMART Total Talus™ System used in conjunction with the Paragon 28® APEX 3D™ Total Ankle Replacement System. The study is expected to begin in early 2024.
ENGLEWOOD, Colo., August 28, 2023--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chairman and CEO and Steve Deitsch, CFO will participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference on Monday, September 11, 2023, at 4:55 p.m. Eastern Time / 2:55 p.m. Mountain Time.
Paragon 28, Inc. (FNA) delivered earnings and revenue surprises of -44.44% and 2.10%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
ENGLEWOOD, Colo., August 02, 2023--Paragon 28, Inc. (NYSE: FNA) ("Paragon 28" or "Company"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended June 30, 2023 and reaffirmed its 2023 net revenue guidance.
ENGLEWOOD, Colo., July 28, 2023--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chairman and CEO, and Steve Deitsch, CFO, will participate in a fireside chat at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, August 9, 2023, at 8:30 a.m. Eastern Time / 6:30 a.m. Mountain Time.
FNA Price Returns